Clinical Trials Browser

Phase 1/2 × Breast Neoplasms × dalpiciclib × Clear all

NCT05176080 2024-12-17

Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Phase 1/2 Terminated

Breast Neoplasms

NCT03772353 2023-03-07

PLEASURABLE

Phase 1/2 Unknown

Breast Neoplasms